/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

ELICIO THERAPEUTICS INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$8.063 0.0676(6.76%) ELTX at 04 Dec 2025 04:30 PM Biotechnology
Lowest Today 7.515
Highest Today 8.16
Today’s Open 7.54
Prev. Close 7.54
52 Week High 12.62
52 Week Low 4.60
Day’s Range: Low 7.515 High 8.16
52-Week Range: Low 4.60 High 12.62
1 day return -
1 Week return -14.04
1 month return -11.67
3 month return -23.18
6 month return -2.66
1 year return +43.47
3 year return -6.72
5 year return -
10 year return -

Institutional Holdings

Market Status

Strong Buy: 1

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 130.13 M

PB Ratio 42.3325

PE Ratio 0.0

Enterprise Value 155.99 M

Total Assets 28.18 M

Volume 132003

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-32896688 -32.9M, FY22:-28207688 -28.2M, FY21:-26400698 -26.4M, FY20:-15712142 -15.7M, FY19:-12260866 -12.3M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-283000 -0.3M, Q2/2025:-281000 -0.3M, Q1/2025:-278000 -0.3M, Q3/2024:null 0.0M, Q2/2024:-293000 -0.3M

Quarterly Net worth Q3/2025:-10083000 -10.1M, Q2/2025:-10561000 -10.6M, Q1/2025:-11209000 -11.2M, Q3/2024:-18838000 -18.8M, Q2/2024:-7229000 -7.2M

Fund house & investment objective

Company Information Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node"targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node"targeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph node"targeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.

Organisation Biotechnology

Employees 32

Industry Biotechnology

CEO Mr. Robert T. Connelly

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow